Core Viewpoint - Alvotech is under investigation by Kirby McInerney LLP for potential violations of federal securities laws following a significant decline in its stock price after receiving a complete response letter from the FDA regarding its biologics license application for AVT05 [1][2]. Company Summary - Alvotech (NASDAQ: ALVO) experienced a stock price drop of $2.62 per share, approximately 34.25%, from $7.65 on October 31, 2025, to $5.03 on November 3, 2025, after the FDA issued a complete response letter related to a failed facility inspection [1]. Legal Context - Kirby McInerney LLP is conducting an investigation on behalf of Alvotech investors concerning possible unlawful business practices by the company or its senior management [1][2]. - The law firm specializes in securities litigation and has a history of achieving recoveries totaling billions of dollars for shareholders [3].

Core Viewpoint - James Hardie Industries plc is facing a federal securities class action lawsuit due to allegations of misleading investors regarding the performance of its North America Fiber Cement segment during a specific period in 2025 [3][4]. Summary by Sections Lawsuit Details - The class action lawsuit is on behalf of investors who purchased James Hardie securities between May 20, 2025, and August 18, 2025 [3]. - The lawsuit claims that the company misrepresented the strength of its North America Fiber Cement segment, despite being aware of inventory destocking by distributors [3]. Financial Impact - On August 19, 2025, James Hardie reported a 12% decline in North American net sales for fiscal Q1 2026, attributing this to lower volumes as customers adjusted inventory levels [4]. - Following the earnings report, the company's share price dropped by $9.79, or approximately 34.4%, from $28.43 to $18.64 [4]. Investor Actions - Investors who acquired James Hardie securities during the class period are encouraged to contact Kirby McInerney LLP to discuss their rights and potential involvement in the lawsuit [2][5].

Core Viewpoint - Rosen Law Firm has announced a class action lawsuit on behalf of purchasers of Perrigo Company plc securities, alleging that the company made materially false and misleading statements regarding its infant formula business and financial results during the class period from February 27, 2023, to November 4, 2025 [1][5]. Group 1: Lawsuit Details - The lawsuit claims that Perrigo's infant formula business, acquired from Nestlé, suffered from significant underinvestment in maintenance and required substantial capital and operational expenditures beyond previously stated estimates [5]. - It is alleged that there were significant manufacturing deficiencies in Perrigo's infant formula facility, leading to overstated financial results, including earnings and cash flow [5]. - The lawsuit asserts that the positive statements made by Perrigo regarding its business operations and prospects were materially misleading and lacked a reasonable basis [5]. Group 2: Participation Information - Investors who purchased Perrigo securities during the class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - To join the class action, investors can visit the provided link or contact Phillip Kim, Esq. for more information [3][6]. - A lead plaintiff must move the court by January 16, 2026, to represent other class members in directing the litigation [1][3].

Core Viewpoint - Rosen Law Firm has announced a class action lawsuit on behalf of purchasers of Skye Bioscience, Inc. securities, alleging that the company made materially false and misleading statements regarding its business and the effectiveness of its product, nimacimab, during the class period from November 4, 2024, to October 3, 2025 [1][5]. Group 1: Lawsuit Details - The class action lawsuit has already been filed, and investors who purchased Skye securities during the specified class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2][5]. - The lawsuit claims that defendants overstated the clinical, regulatory, and commercial prospects of nimacimab, leading to materially false and misleading public statements [5]. Group 2: Participation Information - Investors wishing to join the class action can do so by visiting the Rosen Law Firm's website or contacting their office directly [3][6]. - A lead plaintiff must move the court by January 16, 2026, to represent other class members in directing the litigation [1][3]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest securities class action settlement against a Chinese company [4]. - The firm has been consistently ranked among the top firms for securities class action settlements and has recovered hundreds of millions of dollars for investors [4].

Core Viewpoint - James Hardie Industries plc is facing significant legal and financial challenges following a sharp decline in its stock price and allegations of securities fraud related to misleading statements about inventory levels and customer demand in its North American segment [2][8]. Company Developments - The company announced the departure of its CFO, Rachel Wilson, and appointed Ryan Lada as her replacement on November 17, 2025 [1]. - The stock price collapsed by 34% on August 20, 2025, following the disclosure of poor performance in the North America Fiber Cement division [2][8]. Legal Issues - A class-action lawsuit has been filed against James Hardie and certain executives, alleging securities fraud for misleading investors about inventory levels and customer demand during the class period from May 20, 2025, to August 18, 2025 [4][5]. - The lawsuit seeks damages for violations of the Securities Exchange Act of 1934, specifically Sections 10(b) and 20(a) [4]. Financial Performance - The North America Fiber Cement segment, which generates approximately 80% of the company's total earnings, has been at the center of the allegations [5]. - The company reported a 12% decline in sales for this segment, attributing it to inventory destocking that management had previously denied [7]. Market Reaction - Following the disclosure of the sales decline, the market reacted negatively, resulting in a significant drop in the company's stock price [8]. - The plaintiffs argue that the stock price decline and subsequent investor losses were directly linked to the alleged wrongful acts and omissions by the company's management [8].

Core Viewpoint - Investors in Telix Pharmaceuticals Limited have the opportunity to lead a securities fraud class action lawsuit due to substantial losses incurred as a result of misleading statements made by the company regarding its business operations and prospects [1][3]. Group 1: Lawsuit Details - The lawsuit alleges that between February 21, 2025, and August 28, 2025, Telix's defendants materially overstated the progress made with prostate cancer therapeutic candidates [3]. - The complaint also claims that the quality of Telix's supply chain and partners was materially overstated, leading to misleading positive statements about the company's business [3]. - As a result of these misrepresentations, the defendants' statements lacked a reasonable basis and were materially misleading at all relevant times [3]. Group 2: Participation Information - Investors who suffered losses in Telix Pharmaceuticals are encouraged to contact the Law Offices of Howard G. Smith before January 9, 2026, to participate in the ongoing lawsuit [2][4]. - Interested parties can reach out via email, telephone, or visit the law firm's website for more information regarding their legal rights and the class action [2][4].

San Diego, California--(Newsfile Corp. - November 19, 2025) - Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Freeport-McMoRan Inc. (NYSE: FCX) publicly traded securities between February 15, 2022 and September 24, 2025, both dates inclusive (the "Class Period"), have until January 12, 2026 to seek appointment as lead plaintiff of the Freeport-McMoRan class action lawsuit. Captioned Reed v. Freeport-McMoRan Inc., No. 25-cv-04243 (D. Ariz.), the Freeport-McMoRan class action lawsu ...

Core Viewpoint - A class action lawsuit has been filed against Inspire Medical Systems, Inc. for securities fraud following a significant stock drop due to alleged violations of federal securities laws [1][3]. Company Overview - Inspire Medical Systems, Inc. develops and manufactures an implantable medical device for the treatment of sleep apnea, with its latest product being the Inspire V, which received FDA approval on August 2, 2024 [4]. Allegations and Issues - The lawsuit claims that Inspire misled investors by assuring them that all necessary steps were taken for the launch of Inspire V, which was supposed to meet high demand [5]. - Contrary to these assurances, Inspire allegedly failed to prepare clinicians and payors adequately, leading to significant delays in the device's adoption and weak demand due to excess inventory of older devices [6]. Stock Performance and Impact - On August 4, 2025, Inspire announced that the launch of Inspire V would face an "elongated timeframe," resulting in a reduction of its 2025 earnings per share guidance by over 80% [7]. - Following this announcement, Inspire's stock price dropped by $42.04 per share, or more than 32%, from $129.95 on August 4, 2025, to $87.91 on August 5, 2025 [8].

Core Viewpoint - A class action lawsuit has been filed against Stride, Inc. for securities fraud, following significant stock drops attributed to alleged violations of federal securities laws [1][3]. Company Overview - Stride, Inc. is an education technology company that provides an online platform for students across the U.S. [4]. Allegations - The lawsuit claims that Stride inflated enrollment numbers by retaining "ghost students," failed to comply with employee background checks and licensure laws, and provided a poor customer experience leading to higher withdrawal rates and lower conversion rates [4][5]. Stock Performance - On September 14, 2025, Stride's stock dropped by $18.60, or over 11%, from $158.36 to $139.76 per share following the fraud allegations [5]. - On October 28, 2025, Stride admitted to issues with customer experience, resulting in an estimated 10,000-15,000 fewer enrollments, causing the stock to plummet by $83.48, or more than 54%, from $153.53 to $70.05 per share [6]. Legal Proceedings - Investors have until January 12, 2026, to request to lead the case in the U.S. District Court for the Eastern District of Virginia [3]. - The lawsuit is titled MacMahon v. Stride, Inc., et al., No. 1:25-cv-02019 [3]. Investor Actions - Investors are encouraged to submit their information to the law firm representing the class action, with no upfront costs for shareholders [8].

FCX LAWSUIT: Freeport-McMoRan Inc. Investors are Notified to Contact BFA Law about the Filed Securities Fraud Class Action and Important January 12 DeadlineNovember 19, 2025 3:36 PM EST | Source: Bleichmar Fonti & AuldNew York, New York--(Newsfile Corp. - November 19, 2025) - Leading securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against Freeport-McMoRan Inc. (NYSE: FCX) and certain of the Company's senior executives for securities fraud aft ...